Prof. Chantal Mathieu explains the progress being made with disease-modifying therapy for type 1 diabetes and how it has the potential to transform the current treatment landscape.

Prof. Marion Subklewe explores the interplay between the gut microbiota and the efficacy and safety of CAR T-cell therapy in people with hematologic malignancies.

Prof. Susanne Wegener discusses her team’s work to develop deep learning models that outperform neurologists in predicting patients’ clinical outcomes after stroke.

A conversation with Dr. Luis Paz-Ares about the key questions raised by the ADAURA trial of adjuvant osimertinib in early-stage NSCLC.

Drs Niels Holm and Lene Andreasen explore the latest data on OCT and discuss its potential as an effective approach in PCI.

Professor Andrew Beggs discusses best practice in the use of next-generational sequencing within thyroid and non-small cell lung cancers. This content is intended only for healthcare providers and was made possible by educational funding provided by Illumina, Inc., and Eli Lilly and Company

Prof. Malin Parmar explains why stem cell therapy is such a good option for patients with Parkinson’s disease and how its safety is being tested in the STEM-PD trial.

Professors Morris Brown and Bryan Williams join Jane Godsland to explore the theories behind resistant hypertension, and the latest treatment approaches.

We speak to Dr. Elena Castro about the latest data on PARP inhibitors in prostate cancer as presented at this year's ASCO Genitourinary Cancers Symposium.

We talk to Dr. Nathalie van Havre and Dr. Elsbeth Headley about ongoing medical education in the digital age.

Dr. Jane Godsland & Dr. Erik Heintz discuss the vision for Springer Medicine and offer some teasers for what's to come.